Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Gsk Plc ADR (NY: GSK ) 36.88 +0.12 (+0.33%) Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Gsk Plc ADR < Previous 1 2 3 4 Next > New Data for AREXVY, GSK’s Respiratory Syncytial Virus Vaccine, Show Potential to Help Protect a Broader Group of Adults at Increased Risk for RSV Disease October 24, 2024 From GSK plc Via Business Wire GSK Presents Positive Data for AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Indicating Protection Over Three RSV Seasons October 08, 2024 From GSK plc Via Business Wire Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer’s and More October 03, 2024 Via Investor Brand Network Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer’s and More October 03, 2024 EQNX::TICKER_START (NYSE:ANVS),(NYSE:JNJ),(NYSE:NVS),(NYSE:MRK),(NYSE:GSK) EQNX::TICKER_END Via FinancialNewsMedia Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut September 20, 2024 Wave Life Sciences has received recent Wall Street price targets forecasting big upside. The company has a potentially "industry-leading" treatment. Via MarketBeat Topics Economy Exposures Interest Rates Alector Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024) September 19, 2024 From Alector, Inc. Via GlobeNewswire GSK Announces Positive Topline Data on Co-Administration of AREXVY and SHINGRIX September 18, 2024 From GSK plc Via Business Wire BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Release Promising Clinical Data As Global Alzheimer’s Disease Therapeutics Market Grows August 07, 2024 Via Investor Brand Network Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12% August 06, 2024 From Myriad Genetics, Inc. Via GlobeNewswire Lucrative Incentive for Biotechs as Global Alzheimer’s Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033 August 06, 2024 EQNX::TICKER_START (NYSE:ANVS),(NYSE:PFE),(NYSE:LLY),(NYSE:GSK),(NYSE:NVO) EQNX::TICKER_END Via FinancialNewsMedia US FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit August 01, 2024 From GSK plc Via Business Wire Lucrative Incentive for Biotechs as Global Alzheimer's Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033 August 06, 2024 From FN Media Group LLC Via GlobeNewswire Positive News is Driving This Cancer Drug Maker’s Stock Higher July 15, 2024 IDEAYA Biosciences stock is up more than 16% on positive treatment data in a Phase 2 clinical trial, but after a 76% run-up, IDYA stock may need a breather Via MarketBeat GSK Begins Shipping Influenza Vaccine Doses for 2024-25 Season July 11, 2024 From GSK plc Via Business Wire Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth June 20, 2024 EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GOVX),(NYSE:GSK),(NASDAQ:AZN),(NYSE:MRK) EQNX::TICKER_END Via FinancialNewsMedia Topics Death Exposures Death US FDA Approves Expanded Age Indication for GSK’s AREXVY, the First Respiratory Syncytial Virus (RSV) Vaccine for Adults Aged 50-59 at Increased Risk June 07, 2024 From GSK plc Via Business Wire Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth June 20, 2024 From FN Media Group LLC Via GlobeNewswire Jemperli (dostarlimab-gxly) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer June 03, 2024 From GSK plc Via Business Wire Belantamab Mafodotin combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma June 02, 2024 From GSK plc Via Business Wire Akebia Therapeutics Surges on FDA Approval for Anemia Treatment April 03, 2024 Akebia Therapeutics Inc. (NASDAQ: AKBA) is a biopharmaceutical company specializing in developing treatments for chronic kidney diseases (CKD) and anemia Via MarketBeat Exposures Product Safety Positive RUBY phase III data show potential for Jemperli (dostarlimab-gxly) combinations in more patients with primary advanced or recurrent endometrial cancer March 16, 2024 From GSK plc Via Business Wire GSK Doubles COiMMUNITY Grant Funding, Launches Patient Resources, as Adult Vaccination Rates Begin to Show Promising Rise March 07, 2024 From GSK plc Via Business Wire Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer’s Disease February 08, 2024 The trial, being conducted in partnership with GSK, is expected to enroll approximately 282 patients globally From Alector, Inc. Via GlobeNewswire 23andMe Reports Third Quarter Fiscal 2024 Financial Results February 07, 2024 Announced new non-exclusive data license with GSK, introduced 23andMe Total Health™, and received FDA clearance for IND on novel, dual-mechanism immuno-oncology asset 23ME-1473 From 23andMe, Inc. Via GlobeNewswire FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN) February 07, 2024 From Alector, Inc. Via GlobeNewswire GSK’s RSV Vaccine, AREXVY, Accepted Under Priority Review in US for the Prevention of RSV Disease in Adults Aged 50-59 at Increased Risk February 06, 2024 From GSK plc Via Business Wire Elegen and GSK Sign Collaboration and Licensing Agreement to Further Develop Elegen’s Cell-Free DNA Production Technology January 24, 2024 From Elegen Via Business Wire GSK Enters Agreement to Acquire Aiolos Bio January 09, 2024 From Aiolos Bio, Inc. Via Business Wire GlaxoSmithKline PLC (NYSE: GSK) Records 52-Week High Monday Morning January 08, 2024 Via Investor Brand Network GSK Awards $1M in COiMMUNITY Initiative Grants to Support Adult Immunization and Health Equity December 12, 2023 From GSK plc Via Business Wire < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
